Home›Ustekinumab

Ustekinumab

Also known as: Steqeyma, Wezlana, Otulfi, Selarsdi +5 more

Interleukin-12 AntagonistInterleukin-23 AntagonistInterleukin-12 Antagonists

Route: Subcutaneous, Intravenous

13 interactions on record

Ustekinumab has 13 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Allergen Immunotherapy, Azathioprine, Corticosteroids. Patients taking Ustekinumab should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 13
Moderate: 6

Moderate (6)

Ustekinumab + Allergen Immunotherapy— Ustekinumab may decrease protective effect of allergen immunotherapy, increasing risk of allergic reaction; caution advi…
Ustekinumab + Azathioprine— Immunomodulator used concomitantly in approximately 30% of subjects with Crohn's disease and ulcerative colitis; did not…
Ustekinumab + Corticosteroids— Used concomitantly in approximately 40-50% of CD/UC subjects; safety and efficacy not adversely affected by combination.
Ustekinumab + Decitabine— Immunomodulator used concomitantly in approximately 30% of CD/UC subjects; safety and efficacy not adversely affected by…
Ustekinumab + Mercaptopurine— Immunomodulator used concomitantly in approximately 30% of CD/UC subjects; safety and efficacy not adversely affected by…
Ustekinumab + Methotrexate— Immunomodulator used concomitantly; in psoriatic arthritis trials, concomitant use did not influence safety or efficacy …

Ustekinumab + Allergen Immunotherapy🟡Moderate

Ustekinumab may decrease protective effect of allergen immunotherapy, increasing risk of allergic reaction; caution advised, particularly for anaphylaxis risk.

Ustekinumab + Azathioprine🟡Moderate

Immunomodulator used concomitantly in approximately 30% of subjects with Crohn's disease and ulcerative colitis; did not appear to influence overall safety or efficacy.

Ustekinumab + Corticosteroids🟡Moderate

Used concomitantly in approximately 40-50% of CD/UC subjects; safety and efficacy not adversely affected by combination.

Ustekinumab + Decitabine🟡Moderate

Immunomodulator used concomitantly in approximately 30% of CD/UC subjects; safety and efficacy not adversely affected by combination.

Ustekinumab + Mercaptopurine🟡Moderate

Immunomodulator used concomitantly in approximately 30% of CD/UC subjects; safety and efficacy not adversely affected by combination.

Ustekinumab + Methotrexate🟡Moderate

Immunomodulator used concomitantly; in psoriatic arthritis trials, concomitant use did not influence safety or efficacy of ustekinumab.

Ustekinumab + Ustekinumab-Aauzℹ️Unknown

7 DRUG INTERACTIONS 7.1 Concomitant Therapies In trials in subjects with plaque psoriasis, the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab.

Ustekinumab + Ustekinumab-Aeknℹ️Unknown

7 DRUG INTERACTIONS 7.1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab.

Ustekinumab + Ustekinumab-Auubℹ️Unknown

Ustekinumab + Ustekinumab-Hmnyℹ️Unknown

7 DRUG INTERACTIONS 7.1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab.

Ustekinumab + Ustekinumab-Srlfℹ️Unknown

Ustekinumab + Ustekinumab-Stbaℹ️Unknown

Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab.

Ustekinumab + Ustekinumab-Ttweℹ️Unknown

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.